EGFR-TKIs inhibit tumor growth by blocking the activation of EGFR in cancer cells and the downstream MAPK (RAS/RAF/MEK/ERK) and PI3K/AKT/mTOR signaling pathways. This evidence concerns the gene MAP2K7 and neoplasm.